| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yasmin A Harrington, Marco Paolini, Lidia Fortaner-Uyà, Melania Maccario, Elisa M T Melloni, Sara Poletti, Cristina Lorenzi, Raffaella Zanardi, Cristina Colombo, Francesco Benedett. History of Peripartum Depression Moderates the Association Between Estradiol Polygenic Risk Scores and Basal Ganglia Volumes in Major Depressive Disorder. Biological psychiatry. Cognitive neuroscience and neuroimaging. 2024-10-03. PMID:39362408. |
history of peripartum depression moderates the association between estradiol polygenic risk scores and basal ganglia volumes in major depressive disorder. |
2024-10-03 |
2024-10-07 |
Not clear |
| Ida Kupcova, Lubos Danisovic, Sona Bernatova, Stefan Harsany. Analysis of Salivary Neuropeptides in Anxiety and Depression Using the Luminex MAGPIX® System. Cureus. vol 16. issue 8. 2024-09-30. PMID:39347144. |
anxiety and depressive disorders are highly prevalent mental health conditions, affecting millions worldwide. advancements in neurobiology have identified the effects of various neuropeptides in modulating mood and stress responses. some of the well-researched neuropeptides in plasma are oxytocin (oxt), alpha-melanocyte-stimulating hormone (alpha-msh), beta-endorphin, neurotensin, and substance p. in this study, we used methods of liquid biopsy to acquire saliva samples to analyze the concentrations of neuropeptides associated with depression. |
2024-09-30 |
2024-10-02 |
Not clear |
| Adriano Alberti, David Richer Araujo Coelho, Willians Fernando Vieira, Betine Moehlecke Iser, Rose Meiry Fernandez Lampert, Eliane Traebert, Bruna Becker da Silva, Bruna Hoffmann de Oliveira, Graziela Marques Leão, Gabriela de Souza, Fabiana Meneghetti Dallacosta, Gabriela Kades, Kristian Madeira, Matheus Uba Chupel, Fernando Schorr Grossl, Renan Souza, Ben Hur Soares, Ricelli Endrigo Ruppel da Rocha, Erica da Silva Sipriano, Daniel Fernandes Martins, Lenita Agostinett. Factors Associated with the Development of Depression and the Influence of Obesity on Depressive Disorders: A Narrative Review. Biomedicines. vol 12. issue 9. 2024-09-28. PMID:39335507. |
factors associated with the development of depression and the influence of obesity on depressive disorders: a narrative review. |
2024-09-28 |
2024-10-01 |
Not clear |
| Xiaofeng Wu, Xiaojun Shen, Qinghe Li, Peiyuan Wan. Temporal dynamic alterations of regional homogeneity in major depressive disorder: a study integrating machine learning. Neuroreport. vol 35. issue 15. 2024-09-23. PMID:39311716. |
additionally, receiver operating characteristic curve results of the dynamic regional homogeneity values in the left precuneus and right postcentral gyrus could distinguish major depressive disorder patients from healthy controls; furthermore, changes in the dynamic regional homogeneity were correlated with depression severity. |
2024-09-23 |
2024-09-26 |
Not clear |
| Olayinka I Arimoro, Colin B Josephson, Matthew T James, Scott B Patten, Samuel Wiebe, Lisa M Lix, Tolulope T Sajob. Screening for depression in patients with epilepsy: same questions but different meaning to different patients. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2024-09-09. PMID:39249715. |
patient-reported outcome measures (proms) such as the neurological disorders depression inventory in epilepsy (nddi-e), a 6-item epilepsy-specific prom, is used to screen for major depressive disorder symptoms for patients with epilepsy (pwe). |
2024-09-09 |
2024-09-11 |
Not clear |
| Joshua T Jordan, Li Shen, Nicholas J Cooper, Samantha V Goncalves, Madhukar H Trivedi, Alan F Schatzberg, Wei Wu, Adam J Savitz, Amit Etki. Baseline Cognition Is Not Associated With Depression Outcomes in Vortioxetine for Major Depressive Disorder: Findings From Placebo-Controlled Trials. The Journal of clinical psychiatry. vol 85. issue 4. 2024-09-06. PMID:39240698. |
baseline cognition is not associated with depression outcomes in vortioxetine for major depressive disorder: findings from placebo-controlled trials. |
2024-09-06 |
2024-09-09 |
Not clear |
| Naigang Li, Jingyi Du, Ying Yang, Tiantian Zhao, Dong Wu, Fan Peng, Dongshuang Wang, Linghua Kong, Wenjuan Zhou, Aijun Ha. Microglial PCGF1 alleviates neuroinflammation associated depressive behavior in adolescent mice. Molecular psychiatry. 2024-08-30. PMID:39215186. |
in this study, we found that the expression of polycomb group 1 (pcgf1), an important epigenetic regulator, was decreased both in the plasma of adolescent major depressive disorder (mdd) patients and in the microglia of adolescent mice in a mouse model of depression. |
2024-08-30 |
2024-09-04 |
mouse |
| Jadwiga Naji. The role of psilocybin in depressive disorders. Current medical research and opinion. 2024-08-23. PMID:39177339. |
a review of psilocybin use in patients with depressive disorders is presented.a search was conducted investigating the use of psilocybin in patients with depressive disorders and treatment resistant depression via pubmed/medline, embase, and google scholar in october 2023; all publication types were permitted and limited for english-language. |
2024-08-23 |
2024-08-25 |
Not clear |
| Jadwiga Naji. The role of psilocybin in depressive disorders. Current medical research and opinion. 2024-08-23. PMID:39177339. |
controlled and uncontrolled clinical trials utilizing psilocybin with psychological support for major depressive disorder and treatment-resistant depression, as well as in patients with depression and cancer related anxiety have demonstrated immediate and sustained antidepressant and anxiolytic effects. |
2024-08-23 |
2024-08-25 |
Not clear |
| Jadwiga Naji. The role of psilocybin in depressive disorders. Current medical research and opinion. 2024-08-23. PMID:39177339. |
depression is a serious psychiatric disorder with a high incidence of morbidity and mortality and psilocybin with psychotherapy has emerged as a promising potential in the treatment of depressive disorders. |
2024-08-23 |
2024-08-25 |
Not clear |
| Jadwiga Naji. The role of psilocybin in depressive disorders. Current medical research and opinion. 2024-08-23. PMID:39177339. |
keyword search terms included: "psilocybin" or "psychedelics" and "depression", or "major depressive disorder", or "treatment-resistant depression". |
2024-08-23 |
2024-08-25 |
Not clear |
| Mariana Zarankin, María S Pellegrini, Francisco Zenten. Psilocybin fungi microdose treatment in major depressive disorder: a case report Vertex (Buenos Aires, Argentina). vol 35. issue 164, abr.-jun.. 2024-07-18. PMID:39024488. |
psilocybin fungi microdose treatment in major depressive disorder: a case report major depression disorder is an entity with high prevalence and worldwide impact. |
2024-07-18 |
2024-09-08 |
Not clear |
| Cui Lyu, Xinyue Lyu, Qiyong Gong, Bo Gao, Yiming Wan. Neural activation signatures in individuals with subclinical depression: A task-fMRI meta-analysis. Journal of affective disorders. 2024-06-23. PMID:38909758. |
previous task-related functional magnetic resonance imaging (task-fmri) investigations have documented abnormal brain activation associated with subclinical depression (sd), defined as a clinically relevant level of depressive symptoms that does not meet the diagnostic criteria for major depressive disorder. |
2024-06-23 |
2024-06-26 |
Not clear |
| Hitoshi Osaka, Tetsufumi Kanazaw. Emerging trends in antipsychotic and antidepressant drug development: Targeting nonmonoamine receptors and innovative mechanisms. PCN reports : psychiatry and clinical neurosciences. vol 2. issue 4. 2024-06-13. PMID:38868733. |
another notable candidate is zuranolone, operating as a gaba a receptor-positive allosteric modulator, showcasing efficacy in treating major depressive disorder (mdd) and postpartum depression. |
2024-06-13 |
2024-06-15 |
Not clear |
| Andrea N Georgiou, Konstantinos Voskarides, Panos Zanos, Andreas Chatzittofi. Investigating the shared genetic basis and causal relationships between mucosa-associated lymphoid tissue inflammation and psychiatric disorders. Frontiers in psychiatry. vol 15. 2024-05-14. PMID:38742127. |
in the present study, we investigated this association, using as proxies genetically predicted tonsillectomy, appendectomy and appendicitis on psychiatric disorders including major depressive disorder (mdd), schizophrenia (scz), bipolar depression (bd) and anxiety (anx) via a two-sample mendelian randomization (mr) analysis. |
2024-05-14 |
2024-05-27 |
Not clear |
| Jiao Cheng, Lin Yuan, Shuwen Yu, Bing Gu, Qian Luo, Xixi Wang, Yijing Zhao, Chengcheng Gai, Tingting Li, Weiyang Liu, Zhen Wang, Dexiang Liu, Roger C M Ho, Cyrus S H H. Programmed cell death factor 4-mediated hippocampal synaptic plasticity is involved in early life stress and susceptibility to depression. Behavioural brain research. vol 468. 2024-05-11. PMID:38723677. |
combined, these results suggest that pdcd4 may play an important role in the els-induced susceptibility to depression and, thus, may become a therapeutic target for depressive disorders. |
2024-05-11 |
2024-05-27 |
mouse |
| Mengjia Ji, Junfei Feng, Guirong Li. Efficacy and safety of aripiprazole or bupropion augmentation and switching in patients with treatment-resistant depression or major depressive disorder: A systematic review and meta-analysis of randomized controlled trials. PloS one. vol 19. issue 4. 2024-04-26. PMID:38669232. |
to report the first and largest systematic review and meta-analysis of randomized controlled trials (rct) to evaluate the efficacy and safety of aripiprazole or bupropion augmentation and switching in patients with treatment-resistant depression (trd) or major depressive disorder(mdd). |
2024-04-26 |
2024-04-29 |
Not clear |
| Mengjia Ji, Junfei Feng, Guirong Li. Efficacy and safety of aripiprazole or bupropion augmentation and switching in patients with treatment-resistant depression or major depressive disorder: A systematic review and meta-analysis of randomized controlled trials. PloS one. vol 19. issue 4. 2024-04-26. PMID:38669232. |
efficacy and safety of aripiprazole or bupropion augmentation and switching in patients with treatment-resistant depression or major depressive disorder: a systematic review and meta-analysis of randomized controlled trials. |
2024-04-26 |
2024-04-29 |
Not clear |
| David John Hallford, David W Austin, Keisuke Takano, Joesph J Yeow, Danielle Rusanov, Matthew Fuller-Tyszkiewicz, Filip Rae. Improving usual care outcomes in major depression in youth by targeting memory specificity: A randomized controlled trial of adjunct computerized memory specificity training (c-MeST). Journal of affective disorders. 2024-04-25. PMID:38663556. |
extending on previous findings that computerized mest (c-mest) improves memory specificity and depressive symptoms in major depressive disorder (mdd) in adults, this study aimed to assess the effects of c-mest in youth with mdd on memory specificity and depression in addition to other treatment. |
2024-04-25 |
2024-04-28 |
Not clear |
| Ahmad Shamabadi, Hanie Karimi, Mohammad Ali Fallahzadeh, Salar Vaseghi, Razman Arabzadeh Bahri, Bita Fallahpour, Amir Hossein Abdolghaffari, Shahin Akhondzade. Sex-controlled differences in sertraline and citalopram efficacies in major depressive disorder: a randomized, double-blind trial. International clinical psychopharmacology. 2024-04-19. PMID:38640201. |
to investigate the response to antidepressants while controlling for sex, which has been controversial, 92 outpatient males and females with major depressive disorder were assigned to sertraline (100 mg/day) or citalopram (40 mg/day) in two strata and were assessed using hamilton depression rating scale (hdrs) scores and brain-derived neurotrophic factor (bdnf), interleukin (il)-6 and cortisol serum levels in this 8-week, randomized, parallel-group, double-blind clinical trial. |
2024-04-19 |
2024-04-22 |
Not clear |